VC fund profile · evidence-aware directory data
Sound Bioventures stages, portfolio and investment profile
Sound Bioventures is a life-sciences venture investor. It co-led Altay Therapeutics' $37 million Series A, announced closed on October 14, 2026, to advance its investigational oral DUX4 inhibitor for FSHD. Sound's individual check size was not disclosed.
Keep track of Sound Bioventures
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Series A
Participates: Not recorded
Sector focus
biotech-life-sciences
Geography
Not recorded
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
1
Linked startup profiles
Latest fund vehicle
Not recorded
Vehicle name, size, and vintage are not yet structured.
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: 2026-10-15T07:20:00Z. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Portfolio companies we track
Startups in our directory that list Sound Bioventures as an investor (1 total).
Related investment articles
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.